Medclair AB (”Medclair” eller ”Bolaget”) är idag den enda aktören som erbjuder mobila lösningar för ...
Orders recover sharply, +30% y-o-y, and sales beat our est.
Solid Q4 finish but cautious Q1/H1'25 guidance Pick-up in OEM/VIP but destocking holds back AM Negat...
Utvecklingen inom portföljbolagen visar på förbättring, där nu Voi uppnått ett positivt rörelseresul...
Redeye states AVTECH delivered a solid report in line with preliminary figures and beat Redeye Resea...
Q4 is a reminder that Ascelia ticked some essential boxes during 2024, including completing a succes...
Redeye comments on Leqembi’s Q4 sales, which were a bit better than we expected, disclosed earlier t...
Redeye states Gapwaves Q4 2024 report was better than expected Redeye Research Estimates and the con...
Redeye updates its estimates after reviewing Tessin's Q4 report, which came in below our expectation...
Redeye updates its estimates following CTEK’s Q4 report, which was largely impacted by General Motor...
LapWall’s Q4 was slightly stronger than we expected in terms of profitability.
Redeye revised its update on Enea after uncovering errors in its financial model.
Fiskars' Q4 results were in line with expectations and the company issued positive guidance for 2025...
Redeye reinforces its positive view of Transtema following a strong Q4, where Sweden improved substa...
Analysguiden ser ljust på framtiden för Eastnine efter årets två förvärv i Polen.
On February 6th, Eevia Health published the Company’s quarterly report for Q4-24.
DT’s Q4 results came in largely as expected as EBITA improved by EUR 0.
LapWall's fourth quarter performance was solid, despite net sales falling 13% y/y.
Redeye provides a research note on Faron Pharmaceuticals following the outcome of the company’s rece...
Redeye presents its preview for Devyser’s Q4 2024 report, due on February 13.
